| Species |
Mouse |
| Protein Construction |
FGF-R3(ⅢC) (Glu21-Gly374)
Accession # Q61851-1 |
mFc |
| N-term |
C-term |
|
| Purity |
> 90% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 1 EU/μg of protein by gel clotting method |
| Expression System |
CHO |
| Apparent Molecular Weight |
~92.6 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
Fibroblast growth factor receptor 3(FGFR3) also known as CD333 (cluster of differentiation 333) is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. The FGFR3 gene produces various forms of the FGFR3 protein and the location varies depending on the isoform of the FGFR3 protein. Since the different forms are found within different tissues, the protein is responsible for multiple growth factor interactions. Gain of function mutations in FGFR3 inhibits chondrocyte proliferation and underlies achondroplasia and hypochondroplasia. |
| Synonyms |
CD_antigen: CD333; Mfr3; Sam3; Heparin-binding growth factor receptor |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
